Showing results (171-180 of 233) with videos related to

Sort By:
Pageof 24
The New England Journal of Medicine|October 23, 2014
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancerFotios Loupakis, Chiara Cremolini, Gianluca Masi, et al.
Scientific Reports|April 28, 2016
Angiogenesis genotyping and clinical outcome during regorafenib treatment in metastatic colorectal cancer patientsRiccardo Giampieri, Lisa Salvatore, Michela Del Prete, et al.
British Journal of Cancer|July 13, 2021
CEA increase as a marker of disease progression after first-line induction therapy in metastatic colorectal cancer patients. A pooled analysis of TRIBE and TRIBE2 studiesRoberto Moretto, Daniele Rossini, Veronica Conca, et al.
Cancers|November 25, 2023
Primary Tumor Resection in Synchronous Metastatic Colorectal Cancer Patients Treated with Upfront Chemotherapy plus Bevacizumab: A Pooled Analysis of TRIBE and TRIBE2 StudiesValentina Fanotto, Daniele Rossini, Mariaelena Casagrande, et al.
The Lancet. Oncology|September 5, 2015
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE studyChiara Cremolini, Fotios Loupakis, Carlotta Antoniotti, et al.
Healthcare (Basel, Switzerland)|December 30, 2025
A New Model for Bone Health Management in Postmenopausal Early Breast Cancer Patients Undergoing Adjuvant Endocrine Therapy-The Predict & Prevent ProjectStefania Gori, Alessandra Fabi, Rossana Berardi, et al.
British Journal of Cancer|October 7, 2020
Treatments after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies by GONODaniele Rossini, Sara Lonardi, Carlotta Antoniotti, et al.
European Journal of Cancer (Oxford, England : 1990)|August 27, 2025
FOLFOXIRI/bevacizumab versus doublets/bevacizumab as initial therapy of unresectable liver-only, right-sided and/or RAS or BRAF mutated metastatic colorectal cancer: An individual patient data-based pooled analysis of randomized trialsCarlotta Antoniotti, Federica Marmorino, Daniele Rossini, et al.
British Journal of Cancer|February 9, 2023
Trop-2 and Nectin-4 immunohistochemical expression in metastatic colorectal cancer: searching for the right population for drugs' developmentRoberto Moretto, Marco Maria Germani, Mirella Giordano, et al.
JCO Precision Oncology|November 7, 2024
KRASG12D-Mutated Metastatic Colorectal Cancer: Clinical, Molecular, Immunologic, and Prognostic Features of a New Emerging Targeted AlterationRoberto Moretto, Daniele Rossini, Sabina Murgioni, et al.
Pageof 24